Un programme de recherche pour innover les soins psychosociaux et promouvoir la santé mentale chez des patients atteints d'un cancer en stade avancé basé sur des fondements conceptuels incluant les determinants biologiques
My overall research program aims to implement and evaluate interventions targeting early determinants of mental health, with a major focus on head and neck oncology. Patients with head and neck cancer have been understudied despite presenting higher levels of psychological distress, physical symptom burden, and morbidity, compared to patients in general oncology. I propose a 4-year research program to extend the work I carried out during my previous 2014-2018 FRQS Junior 1 Clinician-Scientist Salary Award, comprising the extension of three current studies and two new studies proposed for funding: Study 1) 2015-2020 – a randomized controlled trial of the Meaning-Making intervention for newly diagnosed advanced cancer patients currently funded by the CIHR; Study 2) 2018-2019 – a continuation of current analyses of our existing large longitudinal dataset in 223 head and neck cancer patients, which was funded by the FRQS and includes genetic analyses; Study 3) 2018-2021 – extension of this dataset to cover a five-year period, allowing the study of longer-term trajectories of quality of life and mental health outcomes; Study 4) 2018-2020 – a pilot randomized controlled trial of PTSD Coach for newly diagnosed head and neck cancer patients submitted to CIHR for funding; and Study 5) 2020-2023 – an eventual full randomized controlled trial of PTSD Coach based on the pilot.
This Clinician-Scientist Salary Award will support a highly innovative and productive research program, which has and will continue to have an important impact on identifying algorithms for early recognition of head and neck cancer patients at risk of deteriorated mental health, psychological distress, and quality of life compromise during their illness and treatment trajectory. This will lead to the implementation of preventive interventions designed to reduce head and neck cancer disease burden in what is considered one of the most challenging and vulnerable populations in oncology